Home » Stocks » Checkmate Pharmaceuticals

Checkmate Pharmaceuticals, Inc. (CMPI)

Stock Price: $10.67 USD -0.78 (-6.81%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 228.73M
Revenue (ttm) n/a
Net Income (ttm) -28.90M
Shares Out 21.44M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $10.67
Previous Close $11.45
Change ($) -0.78
Change (%) -6.81%
Day's Open 11.46
Day's Range 10.48 - 11.95
Day's Volume 579,721
52-Week Range 10.48 - 16.49

More Stats

Market Cap 228.73M
Enterprise Value 224.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 21.44M
Float 3.24M
EPS (basic) n/a
EPS (diluted) -1.35
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4,551
Short Ratio 0.12
Short % of Float 0.16%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.96
Revenue n/a
Operating Income n/a
Net Income -28.90M
Free Cash Flow n/a
Net Cash 3.93M
Net Cash / Share 0.18
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(138.99% upside)
Current: $10.67
Target: 25.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.89-20.99
Net Income-28.29-20.81
Shares Outstanding10.8410.35
Earnings Per Share-3.23-2.43
Operating Cash Flow-26.85-20.42
Free Cash Flow-26.85-20.42
Cash & Equivalents4.2112.08
Net Cash / Debt4.2112.08
Book Value-97.44-62.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Checkmate Pharmaceuticals, Inc.
Country United States
Employees 22
CEO Barry A. Labinger

Stock Information

Ticker Symbol CMPI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CMPI
IPO Date August 7, 2020


Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts. Address: 245 Main Street, Cambridge, MA, United States, 02142